Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis & Investment Frameworks
Ginkgo Bioworks Holdings, Inc. (DNA) stock analysis on Invetso. Review Ginkgo Bioworks Holdings, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Ginkgo Bioworks Holdings, Inc. Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Ginkgo Bioworks Holdings, Inc. Key Financial Metrics
- Market Cap: $760.27M
- Revenue: $170.16M
- ROE: -56.90%
- ROIC: -27.71%
- Dividend Yield: N/A
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.